Press Releases

This sixth U.S. patent covers unique method used for detection of rare cells including circulating tumor cells

Enters into agreement with HarlePhil Ventures, marking the Company's third announced international distribution partnership

The cerebrospinal fluid (CSF) assay is now validated for melanomas and carcinomas, providing information to help physicians improve treatment decisions for more patients with advanced cancers SAN DIEGO --(BUSINESS WIRE)--Oct. 17, 2022-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular

Biocept now offers 14 clinically actionable biomarker tests, including all validated biomarkers for breast cancer in NCCN Guidelines®

Biocept's OncoCEE(TM) Platform Enhances Ovarian Cancer Research

Fourteenth issued patent covers unique stain for detection of rare cells of interest including circulating tumor cells (CTCs)

Blood-based OncoCEE-BR™ Platform now Includes Estrogen Receptor Testing SAN DIEGO, June 2, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA and circulating tumor cells (CTCs), today

Dr. Marsha A. Chandler and Bruce A. Huebner Bring Life Sciences Relationships

SAN DIEGO --(BUSINESS WIRE)-- Biocept , Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, today announced the launch of its FGFR1 amplification testing utilizing a patient's blood sample.

SAN DIEGO , Aug. 19, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces the expansion of its agreement with MultiPlan,